Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
How does residual DCIS after neoadjuvant chemotherapy impact prognosis if there is a CR of the invasive disease?
Answer from: Radiation Oncologist at Community Practice
The majority of studies suggest residual DCIS has the same outcome as pCR with no invasive disease and thus is still treated as pCR in practice.
Sign in or Register to read more
17488
Related Questions
What are your top takeaways in Breast Cancer from ASCO 2025?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
When utilizing hypofractionated radiotherapy in the post mastectomy setting, are the nodal regions dose painted to a different dose or the same dose as the chest wall/reconstructed breast?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
For patients between 40-49 years old who undergo lumpectomy, how do you choose between offering PBI per the updated PBI guidelines or boosting based on boost guidelines?
In patients with history of prior axillary surgery, subsequently with breast cancer recurrence, and sentinel lymph nodes mapped to internal mammary area (but were not biopsied), do you offer post-mastectomy radiation to cover the IMNs?
In what circumstances would you offer axillary re-irradiation after salvage axillary dissection?
Is re-excision of residual disease ever itself an indication for PMRT?
How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?